Hanwang Technology launches new blood pressure monitor

Hanwang Technology Co Ltd announced the launch of a new generation electronic blood pressure monitor and donation of a batch of monitors to offer a healthcare solution with higher cost performance and contribute to the country's Health China 2030 strategy.

The newly launched electronic blood pressure monitor leverages medical-grade Korotkoff sound technology and integrates five health measurements - blood pressure, atrial fibrillation, pulse pressure, irregular pulses, and tachycardia - into one compact unit, effectively bringing clinical-grade accuracy into everyday households.

The launch of the product challenges the industry's entrenched practice of gradient pricing. Liu Qiutong, director and vice-president of Hanwang Technology, said at the launch ceremony that while basic oscillometric monitors typically retail between 100 yuan ($14) and 200 yuan, accurate devices with clinical-grade capabilities have traditionally been priced over 500 yuan, with some imported brands exceeding 1,000 yuan, creating a significant barrier to reliable home monitoring for millions of patients.

Wang Zengwu, a physician at Beijing-based Fuwai Hospital, Chinese Academy of Medical Sciences, pointed out that China is home to an estimated 270 million hypertensive patients, with a pronounced shortage of accurate and affordable monitoring solutions for grassroots communities. Moreover, hypertension incidence among adults aged 35 to 44 has surged by 74 percent in recent years, creating demand for easy-to-use and cost-effective devices.

Liu emphasized the company's commitment to health equity. "Health equity should not be compromised by pricing tiers. Our goal is to deliver an all-rounder with exceptional cost-performance, enabling more people to benefit from accurate, affordable health monitoring and enjoy the health dividends brought by the technological era."

By incorporating an AI-driven management platform that enables users to track long-term trends, Hanwang fosters a more proactive and connected home-based chronic disease management ecosystem, providing tangible support for the nationwide Healthy China 2030 campaign, the company said.